analiza aiqbench
This study establishes the first unified benchmark for pathway-guided therapy response modeling, revealing that no single deep learning architecture dominates across all clinical tasks. While GraphPath excels in specific prostate cancer scenarios and BINN leads in survival prediction, the results highlight a critical limitation: gene expression data alone cannot effectively predict responses to radiation therapy. For the machine learning community, this underscores the necessity of integrating diverse clinical variables and tailoring model selection to specific therapeutic outcomes rather than seeking a universal solution.
TRAPS: Therapeutic Response Analysis via Pathway-informed Stratification
arXiv:2606.09898v1 Announce Type: new Abstract: Cancer treatment planning requires decisions across multiple clinical dimensions at once. Clinicians must determine whether a patient should receive targeted molecular therapy, radiation therapy, and whether they are likely to survive beyond six months. Existing pathway-informed deep learning models have been developed and tested in isolation, making fair comparison across architectures impossible. We present the first unified benchmark for pathway-guided therapy response modeling, evaluating three biologically informed architectures, BINN, GraphPath, and PATH, across five cancer cohorts drawn from The Cancer Genome Atlas, representing 2,622 patients encoded using Reactome pathway activity scores. Each model is trained jointly on all three clinical outcomes under identical data and evaluation conditions, the first study to treat pathway-structured deep learning as a combined therapy and survival prediction problem. Our results show that no single architecture wins across all tasks: PATH performs best for targeted molecular therapy prediction overall, BINN is most reliable for survival prediction, and no model produces useful predictions for radiation therapy, as the key drivers of that decision are clinical variables not captured in gene expression data. Most strikingly, GraphPath achieves an AUROC of 0.92 on prostate targeted molecular therapy prediction, the highest score in the entire benchmark, demonstrating that lateral co-regulation structure produces exceptional discriminative power when matched to a cohort with a narrow targetable driver programme, even under conditions of extreme class imbalance at only 11\% positive prevalence.
Abstract:Cancer treatment planning requires decisions across multiple clinical dimensions at once. Clinicians must determine whether a patient should receive targeted molecular therapy, radiation therapy, and whether they are likely to survive beyond six months. Existing pathway-informed deep learning models have been developed and tested in isolation, making fair comparison across architectures impossible. We present the first unified benchmark for pathway-guided therapy response modeling, evaluating three biologically informed architectures, BINN, GraphPath, and PATH, across five cancer cohorts drawn from The Cancer Genome Atlas, representing 2,622 patients encoded using Reactome pathway activity scores. Each model is trained jointly on all three clinical outcomes under identical data and evaluation conditions, the first study to treat pathway-structured deep learning as a combined therapy and survival prediction problem. Our results show that no single architecture wins across all tasks: PATH performs best for targeted molecular therapy prediction overall, BINN is most reliable for survival prediction, and no model produces useful predictions for radiation therapy, as the key drivers of that decision are clinical variables not captured in gene expression data. Most strikingly, GraphPath achieves an AUROC of 0.92 on prostate targeted molecular therapy prediction, the highest score in the entire benchmark, demonstrating that lateral co-regulation structure produces exceptional discriminative power when matched to a cohort with a narrow targetable driver programme, even under conditions of extreme class imbalance at only 11\% positive prevalence.
Machine Learning (cs.LG); Multiagent Systems (cs.MA); Quantitative Methods (q-bio.QM)
arXiv:2606.09898 [cs.LG]
(or arXiv:2606.09898v1 [cs.LG] for this version)
https://doi.org/10.48550/arXiv.2606.09898 Focus to learn more arXiv-issued DOI via DataCite
arXivLabs is a framework that allows collaborators to develop and share new arXiv features directly on our website.
Both individuals and organizations that work with arXivLabs have embraced and accepted our values of openness, community, excellence, and user data privacy. arXiv is committed to these values and only works with partners that adhere to them.
Have an idea for a project that will add value for arXiv's community? Learn more about arXivLabs.
Text integral sub licența deschisă a publicației · 326 cuvinte
Subiecte conexe

News
Quantum Computing Report · 7 iun. 2026

News
Quantum Computing Report · 25 iul. 2026
Assessing Information Ecosystems : How Governments Can Get Ahead of Hybrid Threats
carnegieendowment.org · 5 aug. 2026
Construct validity of Claude Opus 4.8's System Card – A commentary
LessWrong · 12 iun. 2026